Dr. Garon on Antiangiogenic Agents in Lung Cancer

Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at University of California, Los Angeles, discusses antiangiogenic agents in patients with lung cancer.

Enthusiasm for antiangiogenic agents has waned although the data have not changed, states Garon. There is a benefit in overall survival, progression-free survival, and an objective response rate when antiangiogenic therapies are added in combination with other agents.